Similarly, in myelodysplastic syndromes (MDS), TP53 mutations correlate with high-risk subtypes and rapid progression to AML, while in chronic lymphocytic leukemia (CLL), 17p deletions co-occurring with TP53 mutations predict resistance to BTK inhibitors 3. This evidence concerns the gene TP53 and myelodysplastic syndrome.